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H I G H L I G H T S
• High levels of Lp(a) may contribute to the residual cardiovascular risk in statin-treated dyslipidemic patients.• Reported data on modulatory effects of statins on plasma Lp(a) levels are inconsistent.• Statin treatment increases Lp(a) levels in patients with dyslipidemia, exclusively in those with the LMW apo(a) phenotype.• The increase in Lp(a) levels upon statin treatment was not associated with common LPA SNPs or change in LDL cholesterol.
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A B S T R A C T
Background and aims: We aimed to evaluate the effect of statin treatment initiation on lipoprotein(a) [Lp(a)]
levels in patients with dyslipidemia, and the interactions with the apolipoprotein(a) [apo(a)] phenotype, LPA
single nucleotide polymorphisms (SNPs) and change in LDL cholesterol.
Methods: The study population consisted of patients with dyslipidemia, predominantly familial hypercholes-
terolemia, who first initiated statin treatment (initiation group; n= 39) or were already on stable statin treat-
ment for at least 4 months (control group; n= 42). Plasma Lp(a) levels were determined with a particle-en-
hanced immunoturbidimetric assay before and at least 2 months after start of statin treatment in individuals of
the initiation group, and at two time points with an interval of at least 2 months in the control group. High and
low molecular weight (HMW and LMW, respectively) apo(a) phenotype was determined by immunoblotting, and
the common LPA SNPs rs10455872, rs3798220 and rs41272110 by Taqman assay.
Results: Plasma Lp(a) levels did not increase significantly in the initiation group (median 20.5 (IQR 10.9–80.7)
to 23.3 (10.8–71.8) mg/dL; p=0.09) nor in the control group (30.9 (IQR 9.2–147.0) to 31.7 (IQR 10.9–164.0)
mg/dL; p=0.61). In patients with the LMW apo(a) phenotype, Lp(a) levels increased significantly from 66.4
(IQR 23.5–148.3) to 97.4 (IQR 24.9–160.4) mg/dL (p=0.026) in the initiation group, but not in the control
group and not in patients characterized by the HMW apo(a) phenotype. Interactions with common LPA SNPs and
change in LDL cholesterol were not significant.
Conclusions: Statins affect Lp(a) levels differently in patients with dyslipidemia depending on the apo(a) phe-
notype. Statins increase Lp(a) levels exclusively in patients with the LMW apo(a) phenotype.
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1. Introduction
An elevated plasma lipoprotein(a) [Lp(a)] level is an established
independent risk factor for cardiovascular disease (CVD) [1–4]. High
levels of Lp(a) may contribute to the considerable residual cardiovas-
cular risk in statin-treated dyslipidemic patients including those with
familial hypercholesterolemia (FH) with LDL-cholesterol below target
levels [5,6]. Lp(a) is an LDL-like particle with an apolipoprotein(a) [apo
(a)] covalently attached to apolipoprotein B100. Lp(a) levels are highly
genetically determined by the number of kringle IV (KIV) copies in the
LPA gene encoding apo(a) [7–12]. Five-to ten-fold higher plasma Lp(a)
levels are found in individuals with at least one low molecular weight
(LMW) apo(a) (≤22 KIV repeats) than in individuals only with high
molecular weight (HMW) apo(a) (≥23 KIV repeats) [13]. Several single
nucleotide polymorphisms (SNPs) in the LPA gene are strongly asso-
ciated with Lp(a) levels and CVD [11,12,14,15]. Although to a limited
extent, non-genetic factors can affect Lp(a) plasma levels, such as for
example weight reduction [16], high saturated fat intake [17,18] or
kidney impairment [19]. Whether statins modify Lp(a) levels is not
clear as inconsistent data have been reported [20–22]. Moreover, the
underlying mechanisms remain to be clarified [21–23]. We hypothe-
sized that the effect of statin treatment on Lp(a) levels depends on the
KIV copy number and/or sequence variations in the LPA gene [24].
To investigate the effect of statin treatment on plasma Lp(a) levels
we determined changes in Lp(a) levels over time in dyslipidemic pa-
tients during the first few months after initiation of statin therapy. As a
control we measured plasma Lp(a) levels at two distinct time points in
dyslipidemic patients who were on stable statin treatment for at least 4
months. Secondly, we examined whether changes in plasma Lp(a) level
induced by statin treatment were associated with apo(a) phenotype,
common SNPs in the LPA gene and change in LDL cholesterol level.
2. Materials and methods
2.1. Study population
Patients aged ≥18 years were consecutively (2011–2015) recruited
at the outpatient cardiovascular genetics clinic at the Erasmus MC,
Rotterdam, the Netherlands. The two study groups both consisted of
patients with dyslipidemia, mostly (~85%) familial hypercholester-
olemia (FH), and were primarily of Caucasian origin. In the initiation
group, patients started statin treatment for the first time (n=39),
whereas in the control group patients were on stable statin treatment
for at least 4 months (n=42). Patients from the initiation group were
newly referred to our tertiary center whereas patients from the control
group were already seen at the outpatient clinic for follow up.
Fasting blood samples were obtained from each patient at 2 dif-
ferent time points with an interval of at least 2 months. In the initiation
group the first time point was immediately before the initiation of statin
treatment. Patients included in the control group did not change statin
type or dose or use of other lipid-lowering drugs between the two blood
sampling time points.
All participants provided written informed consent for blood col-
lection and analysis, sample storage, and usage of biometrical data. This
study was approved by the medical ethical committee of the Erasmus
MC.
2.2. Anthropometric and laboratory measurements
Patient characteristics were recorded at baseline. Whole blood and
plasma samples were stored at −80 °C until further analysis. Total
cholesterol, LDL- and HDL-cholesterol (LDL-C, HDL-C), triglycerides
(TG) and apoB100 were measured using standard laboratory techni-
ques. ‘True LDL-C’ was determined by subtracting Lp(a)-cholesterol
from LDL-C. Lp(a)-cholesterol was calculated from the Lp(a) levels in
nmol/L with the assumptions that the molecular cholesterol-to-
apoB100 ratio, and hence the cholesterol-to-apo(a) ratio, is similar to
that of LDL, and that LDL consists of 25% apoB100 protein en 50%
cholesterol by weight, as described by Viney et al. [25].
Plasma Lp(a) levels (mg/dL or nmol/L) were measured with a
particle-enhanced immunoturbidimetric assay, which is largely in-
dependent of apo(a) kringle IV (KIV) type 2 copy number (Diagnostic
System #171399910930; DiaSys Diagnostic System, GmbH, Germany)
[26]. Baseline and follow-up samples of all participants were measured
in the same run and both samples were close to each other on the plate.
The detection limit of the assay was 3.0 mg/dL and the mean intra-
assay variability was 2.8%. Sampling at two different time points in 28
healthy controls with an interval of 2–4 months did not reveal sig-
nificant changes in Lp(a) level [27]. At baseline, the number of apo(a)
KIV repeats was determined by SDS agarose gel electrophoresis and
immunoblotting, as previously described [26]. When two apo(a) iso-
forms were identified in the blot, either the number of KIV repeats of
the smallest isoform or the mean repeat number of both isoforms was
used in the analysis. According to the number of KIV repeats, patients
were classified as having an LMW apo(a) phenotype when they ex-
pressed at least one apo(a) isoform with ≤22 KIV repeats, or HMW apo
(a) phenotype when they expressed only apo(a) isoforms with ≥23 KIV
repeats.
DNA was isolated using the Invisorb® Blood Universal Kit from
Stratec Molecular (Berlin, Germany). Common variants of the LPA gene
(rs10455872, rs3798220 and rs41272110 (T3888P)) [15,28] were
genotyped with TaqMan allelic discrimination assays, designed and
optimized by Applied Biosystems (Foster City, CA, USA) on a Taqman
Prism 7900 HT platform.
2.3. Statistical analysis
Normality of the data was tested with Shapiro–Wilks test. Differences
between the intervention and the control group at baseline were tested
using χ2 tests with continuity correction, independent samples t tests or
Mann–Whitney U tests, according to the distribution of the data. The
difference in Lp(a) level within the groups was analysed using Wilcoxon
signed ranks tests. The relationship between change in Lp(a) level over
time and apo(a) KIV repeat number was analysed with Spearman's rank
order correlation test. Results with p values of<0.05 were considered
statistically significant. SPSS version 24.0 (IBM corp., Armonk, New
York, USA) and GraphPad Prism version 5 (GraphPad Software, La Jolla,
California, USA) were used for the statistical analyses.
3. Results
3.1. Patient characteristics
Table 1 shows the patient characteristics at baseline. The initiation
group was younger and had higher baseline levels of total cholesterol,
LDL-C and apoB100 than the control group. The median interval be-
tween the two blood sampling time points was 3.8 months (range 2–20
months) in the initiation group and 11.7 months (range 4–26 months)
in the control group.
3.2. Lipoprotein (a) levels
At baseline, median Lp(a) levels were 20.5 (IQR 10.9–80.7) mg/dL
for the initiation group and 30.9 (IQR 9.2–147.0) mg/dL for the control
group (Mann-Whitney U (MWU)=702.5; Z=−1.101; p=0.27). At
the second time point, the median Lp(a) level of the initiation group
was 23.3 (IQR 10.8–71.8) mg/dL, and 31.7 (IQR 10.9–164.0) mg/dL for
the control group (MWU=705.0; Z=−1.078; p= 0.28), which cor-
responds to a relative change of 13.7% (Wilcoxon Z=1.697; p=0.09)
and 2.6% (Z=0.518;p=0.61), respectively. We found no difference
between the two groups in the change of Lp(a) levels (MWU=729.0;
Z=−0.851; p=0.40).
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3.3. Association with apo(a) phenotypes
In both the initiation and control group, 14 patients (36% and 33%,
respectively) had LMW apo(a) phenotype (χ2(1)= 0.000; p=0.99). As
expected, Lp(a) levels at baseline were higher in patients with the LMW
phenotype than with the HMW phenotype (137.8 (IQR 36.8–206.5) vs
15.3 (IQR 6.8–31.5) mg/dL; MWU=184.5, Z=−5.537; p<0.001;
control group and initiation group combined). Fig. 1 shows the change in
Lp(a) by group and apo(a) phenotype. Upon starting statin therapy Lp(a)
increased from 66.4 (IQR 23.5–148.3) to 97.4 (IQR 24.9–160.4) mg/dL
(Z=2.229; p=0.026) in patients with the LMW apo(a) phenotype, but
not in patients with the HMW apo(a) phenotype (14.0 (IQR 8.1–36.8) to
15.1 (IQR 9.5–34.5) mg/dL (Z=0.152; p=0.879)). The change in Lp(a)
upon starting statin therapy was different between the LMW and HMW
subgroups (MWU=91.5; Z=−2.445; p=0.013). In the control group,
Lp(a) levels did not change over time in the LMW subgroup (180.7 (IQR
109.7–236.3) to 190.2 (IQR 97.4–233.3) mg/dL; Z=0.596; p=0.55),
nor in the HMW subgroup (15.6 (IQR 5.9–31.0) to 16.9 (IQR 7.2–34.1)
mg/dL; Z=1.601; p=0.11). Qualitatively similar results were obtained
when Lp(a) levels were expressed in nmol/L.
Next, we analyzed the relationship between Lp(a) levels and the
number of KIV repeats of the smallest apo(a) isoform in the case two
apo(a) isoforms were expressed. Baseline Lp(a) levels were strongly
correlated with the apo(a) KIV repeat number in both the initiation and
the control group (r=−0.589; p<0.001 and r=−0.802; p<0.001,
respectively). The change in Lp(a) level over time significantly corre-
lated with the KIV repeat number in the initiation group but not in the
control group (Spearman's rho −0.424; p=0.007 and 0.079; p=0.62,
respectively). The change in Lp(a) level remained negatively correlated
with apo(a) KIV repeat numbers after correction for baseline Lp(a)
(after Blom-transformation of Lp(a) data; B=−0.542, p=0.036).
Similar results were obtained using the mean KIV repeat number in the
case two apo(a) isoforms were expressed (rho=−0.369, p=0.021
and rho= 0.054, p=0.74, respectively).
3.4. Association with common LPA SNPs
In the combined initiation and control group, carriers of the minor
rs10455872 allele had a higher Lp(a) level at baseline than non-carriers
(172.2 (IQR 83.0–215.1) vs. 18.8 (IQR 8.5–78.8) mg/dL;
MWU=100.0; Z=4.151; p<0.001). In addition, 11 out of 12 carriers
of the rs10455872 minor allele had the LMW phenotype (p<0.001 by
Table 1
Baseline characteristics.
Characteristics Initiation group n=39 Control group n=42 p
Age (years) 39.9 ± 16.3 52.9 ± 14.2 < 0.001
Sex (male) 18 (46%) 22 (52%) 0.74
Follow-up time (months) 3.8 [3.1, 5.7] 11.7 [11.0, 23.1] < 0.001
FHa 33 (85%) 37 (88%) 0.90
LMW apo(a) phenotype 14 (36%) 14 (33%) 0.99
rs10455872b 4 (11%) 8 (19%) 0.45
rs3798220b 0 (0%) 4 (10%) 0.17
rs41272110b 15 (40%) 11 (26%) 0.30
Body mass index (kg/m2) 25.2 ± 3.5 28.1 ± 5.8 0.008
Systolic blood pressure (mmHg) 128 ± 19 135 ± 11 0.05
Diastolic blood pressure (mmHg) 78 ± 9 81 ± 8 0.23
Hypertensionc 9 (23%) 16 (38%) 0.22
Diabetes mellitusc 1 (3%) 4 (10%) 0.40
Smokerc (current, former) 8 (21%) 7 (17%) 0.66
Premature CVD patientc 3 (8%) 9 (21%) 0.15
Total Cholesterol (mmol/L) 7.5 ± 1.9 4.5 ± 0.6 < 0.001
LDL-C (mmol/L) 5.5 ± 1.6 2.6 ± 0.6 < 0.001
‘True LDL-C’ (mmol/L)d 5.3 ± 1.6 2.1 ± 0.9 < 0.001
HDL-C (mmol/L) 1.3 ± 0.4 1.4 ± 0.5 0.67
Triglyceride (mmol/L) 1.8 ± 2.0 1.9 ± 1.9 0.92
Apolipoprotein B 100 (μmol/L) 1.5 ± 0.3 0.9 ± 0.2 < 0.001
Lipoprotein(a) (mg/dL) 20.5 [10.9–80.7] 30.9 [9.2–147.0] 0.27
Apo(a) KIV repeat numbere 27.1 ± 5.6 28.0 ± 6.3 0.65
LMW apo(a) phenotype 14 (36%) 14 (33%) 0.81
Data are mean ± SD or median [IQR].
a Percentage subjects with familial hypercholesterolemia (FH) either genetically or clinically confirmed [39].
b Carriers of the minor allele.
c Percentage subjects smoking (current and former), hypertension (defined as a systolic blood pressure> 140mmHg or a diastolic blood
pressure>90mmHg or the use of anti-hypertensive medication), diabetes mellitus (defined as a fasting glucose> 7mmol/L or the use of anti-
diabetic medication), and premature CVD (defined as a myocardial infarction, stroke or peripheral artery disease with intervention before age 55 for
men and 60 years for women).
d LDL-C after correction for Lp(a)-cholesterol.
e The KIV repeat number of the smallest apo(a) isoform when two different apo(a) isoforms are present on the immunoblot.
Fig. 1. Lp(a) levels at baseline and at follow-up in the subgroups.
This figure shows baseline and follow-up Lp(a) levels in patients with the LMW
and HMW apo(a) phenotype. The continuous line indicates the initiation group
and the dotted line indicates the control group. *p < 0.05.
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Pearson Chi-Square). There was a strong correlation of this SNP with
the LMW vs. HMW phenotype (r=−0.515, p<0.001) as well as with
the KIV repeat number of the smallest apo(a) isoform (r=−0.523,
p<0.001). Lp(a) levels in carriers of the minor rs41272110 allele were
similar to those in the non-carriers (23.6 (IQR 12.5–90.6) vs. 29.0 (IQR
8.6–114.3) mg/dL; MWU=654.5; Z= 0.488; p=0.63). There were
no carriers of the minor rs3798220 allele in the initiation group.
We assessed the association of change in Lp(a) levels with the LPA
SNPs rs10455872 and rs41272110. The changes in Lp(a) levels over
time were not significantly different between the rs10455872 carriers
vs. non-carriers in the initiation group (MWU=29.0; Z=−1.855;
p=0.066) nor in the control group (MWU=125.5; Z=−0.336;
p=0.74). For rs41272110 there were also no significant differences in
Lp(a) changes over time between carriers vs. non-carriers
(MWU=164.5; Z=−0.239; p=0.81 and MWU=134.5;
Z=−1.030; p=0.31, respectively).
3.5. Association with LDL-cholesterol
In the initiation group, LDL-C levels decreased from 5.3 (IQR
4.4–6.4) to 3.1 (IQR 2.6–4.1) mmol/L (Z=5.373; p<0.001) on statin
therapy. In the control group, LDL-C remained stable between the two
time points (2.6 (IQR 2.2–2.9) mmol/L vs 2.7 (IQR 2.2–3.1) mmol/L
(Z=1.277; p=0.202)). Qualitatively similar results were found for
‘true LDL-C’ levels, which were derived from LDL-C by correcting for Lp
(a)-cholesterol. We found no association of LDL-C or ‘true LDL-C’ and Lp
(a) at baseline in the initiation group (rho=−0.109; p=0.52 and
rho=−0.293; p=0.074, respectively). In the control group, LDL-C
was not associated with Lp(a) levels at baseline (rho=−0.014;
p=0.93) but ‘true LDL-C’ did (rho=−0.600; p<0.001). In both
groups, there was no association between change in Lp(a) and change
in LDL-C in both groups (rho=−0.030; p=0.86 and rho=−0.015;
p=0.93, respectively), nor with ‘true LDL-C’ (rho=−0.136; p=0.39
and rho=−0.092; p=0.58, respectively).
4. Discussion
Our data suggest that initiation of statin treatment increases Lp(a)
levels in patients with dyslipidemia, but exclusively in patients with the
LMW apo(a) phenotype. Initiation of statin treatment increased Lp(a) le-
vels by 11.1% in the entire group, which is in line with results of two
recent meta-analyses, showing an increase of 10.6% [29] and 4.14mg/dL
[30]. This average increase in our patients was mainly driven by the
presence of an LMW apo(a) phenotype in whom the increase of Lp(a) level
was roughly almost 50%. We did not find an interaction between Lp(a)
change and common LPA SNPs across the groups, which may have been
due to the low number of minor allele carriers in our study population. A
recent meta-analysis of seven randomized controlled statin trials with
cardiovascular disease outcomes showed no overall effect of 1-year statin-
treatment on plasma Lp(a) levels [31], as Lp(a) levels significantly in-
creased in 3 trials but decreased in 3 other trials. Compared to those trials,
our study included predominantly familial hypercholesterolemia patients
with relatively high baseline Lp(a) levels, who were statin treated for
shorter time. Moreover, we were able to correlate changes in Lp(a) levels
with the number of apo(a) KIV repeats, not only when used as a catego-
rical but also as a continuous variable in the analysis. Lp(a) levels in-
creased to a lesser extent with higher KIV repeat number, which was in-
dependent of baseline levels. To our knowledge, we are the first to show
that the effect of statin treatment on plasma Lp(a) levels in individual
patients depends on the apo(a) phenotype, with Lp(a) levels increasing
exclusively in carriers of at least one apo(a) isoform with≤22 KIV repeats.
The mechanism of this statin-induced increase in Lp(a) level re-
mains unclear. The diagnosis of dyslipidemia and initiation of a statin
could hypothetically have led to increased risk awareness, resulting in a
change in lifestyle including for example less saturated fat-intake.
Reduced fat intake and a shift from dietary saturated to unsaturated fat
have been previously associated with increased Lp(a) levels [17]. Lp(a)
levels increased more upon shift to dietary unsaturated fat in subjects
with high baseline Lp(a) [18], and hence presumably in subjects with
LMW apo(a) phenotype than with HMW apo(a) phenotype. Alter-
natively, statins may indirectly increase plasma Lp(a) levels by upre-
gulation of apo(a) synthesis or reducing Lp(a) clearance. Since smaller
apo(a) isoforms with lower number of KIV repeats are secreted more
efficiently and are cleared less efficiently than larger apo(a) isoforms
[32–35], the statin effect may be more pronounced in subjects with
LMW than the HMW apo(a) phenotype.
We found that ‘true LDL-C’ negatively associated with Lp(a) levels in
patients from the control group, which are stably on statin treatment,
but this did not reach statistical significance for patients in the initia-
tion group at baseline, when not on cholesterol-lowering medication
yet. The higher the levels of apo(a), the more apo(a) may become
bound to LDL particles, thus explaining the negative association be-
tween ‘true LDL-C’ and Lp(a). That this reached statistically significant
levels in the control group only may indicate some degree of over-
correction for Lp(a)-cholesterol, which will have a stronger effect after
than before LDL-C is lowered by statin treatment.
It has long been known that statin treatment affects Lp(a) levels not
in parallel with the lowering of LDL-C. Here, we show that statins even
increase Lp(a) levels while lowering LDL. In addition, we found LDL-C
and ‘true LDL-C’ levels not to be associated with Lp(a) levels over time
after starting statin treatment. In contrast, monoclonal antibodies
against proprotein convertase subtilisin kexin type 9 (PCSK9) have been
shown to reduce Lp(a) levels in parallel with the lowering of LDL-C and
apoB100 [36,37].Recently, Watts et al. [38] showed that PCSK9 in-
hibitors lower Lp(a) levels in healthy individuals by reducing the pro-
duction of Lp(a)-associated apo(a), whereas it increases the clearance of
Lp(a) when LDL-receptor expression is further upregulated by statin
treatment, The mechanism underlying the upregulation of Lp(a) levels
upon treatment of FH patients with a statin remains to be established.
4.1. Strenghts and limitations of the study
Limitations of this study are the small number of subjects included,
the various types and dosages of statins and duration of treatment, the
lack of data on lifestyle (in particular diet), and the observational nature
of the study lacking randomization. Although we found no significant
difference in baseline Lp(a) levels between the initiation and the control
group, the Lp(a) level in the LMW group was higher in the control vs
initiation group. Patients with high Lp(a) levels may be overrepresented
in our control group of dyslipidemia patients who are frequently invited
back at the outpatient clinic of our tertiary center despite being on stable
statin treatment. However, this did not affect the main outcome.
Strengths of this study include Lp(a) measurements of all samples in a
single run and without repeated freezing-thawing cycles, the inclusion of
a control group with constant statin treatment and the determination of
the apo(a) phenotypes and common Lp(a) SNPs.
4.2. Conclusions
Our data shows that statin treatment increases Lp(a) levels in dys-
lipidemic patients with the LMW apo(a) phenotype. This increase was
not associated with common LPA SNPs or change in LDL cholesterol. To
understand the effects of statins and other drugs on Lp(a) levels, more
research is needed on Lp(a) metabolism, including synthesis, clearance
and turnover of apo(a).
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